Indication
Ervebo is indicated for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus. The use of Ervebo should be in accordance with official recommendations.
Loading your page…
Hemorrhagic Fever, Ebola
Marketing Authorisation Holder: Merck Sharp & Dohme B.V.
EMA Authorisation: 11/11/2019
INN: Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live)
AI Drug & Interaction Analysis
Free account required
Ask Osler about Ervebo: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.